While there are no studies on the role of GPR6 in MDD, the selective localization of this receptor in the straiatum [92] and the discovery of endogenous inverse agonists of GPR6 that are dopamine derivatives (N-arachidonoyl dopamine, N-docosahexaenoyl dopamine, N-oleoyl dopamine, and N-palmitoyl dopamine) [93] suggest that GPR6 might be a possible therapeutic target for MDD. The gene discussed is GPR6; the disease is major depressive disorder.